Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.51 |
| ▸ | CNR1 | P21554 | 6/20 | 0.51 |
| ▸ | ACHE | P22303 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6764408 | 0.82 | CNR2 (0.65) | CNR2CNR1ACHELMNAALDH1A1 | |
| SCHEMBL6766646 | 0.78 | KDM4E (0.54) | CNR2CNR1ACHEGAATSHR | |
| SCHEMBL6763450 | 0.77 | CNR2 (0.58) | CNR2CNR1ACHETSHRALDH1A1 | |
| SCHEMBL6762827 | 0.76 | SPHK2 (0.50) | CNR2CNR1ACHEPOLB | |
| SCHEMBL6761965 | 0.76 | CNR2 (0.54) | CNR2CNR1ACHELMNATSHR | |
| SCHEMBL6767172 | 0.76 | CNR2 (0.68) | CNR2CNR1ACHELMNAALDH1A1 | |
| SCHEMBL6763004 | 0.75 | MEN1 (0.47) | CNR2CNR1ACHEBRD4ALDH1A1 | |
| SCHEMBL5372587 | 0.69 | PDE5A (0.55) | CNR2CNR1GAANPSR1LMNA | |
| SCHEMBL8007567 | 0.67 | CNR2 (0.68) | CNR2CNR1ACHELMNAALDH1A1 | |
| SCHEMBL9917403 | 0.65 | CNR2 (0.81) | CNR2CNR1ACHENPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-03-11 | — | — | US | claimed |
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-03-11 | — | — | US | disclosed |
| WO-2003076408-A2 | INDAZOLE DERIVATIVES THAT ARE ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | ABBOTT LABORATORIES (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | GUCY1B1, GUCY1A1, GUCY1A2 | CNR2 1561/4885CNR1 1179/4885ACHE 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.